Cancer Research AACR Membership Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakamura, K.
Right arrow Articles by Kudo, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakamura, K.
Right arrow Articles by Kudo, T.
[Cancer Research 60, 760-765, February 1, 2000]
© 2000 American Association for Cancer Research

Tumor Biology

Down-Regulation of the Insulin-like Growth Factor I Receptor by Antisense RNA Can Reverse the Transformed Phenotype of Human Cervical Cancer Cell Lines1

Keiichiro Nakamura, Atsushi Hongo, Junichi Kodama, Yasunari Miyagi, Mitsuo Yoshinouchi2 and Takafumi Kudo

Department of Obstetrics and Gynecology, Okayama University Medical School, Okayama 700-8558, Japan


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The insulin-like growth factor I receptor (IGF-IR) plays an essential role in the establishment and maintenance of transformed phenotype, and interference with the IGF-IR pathway by antisense or dominant-negative mutants causes reversal of the transformed phenotype in many rodent and human tumor cell lines. We stably transfected an IGF-IR antisense mRNA expression plasmid into human papillomavirus (HPV)-negative C33a cell line, HPV-16-positive SiHa cell line, and HPV-18-positive HeLa S3 cell line to determine whether the IGF-IR could be a target for cervical cancer cells, especially in the presence of HPV. Approximately 30–80% down-regulation of IGF-IR expression was observed by Western blot in antisense transfected clones. There was a little inhibition in monolayer growth in all cell lines. In C33a cells, wild-type and sense clones formed 92–146 colonies in soft agar after 3 weeks; antisense clones formed <12 colonies. In SiHa cells, wild-type and sense clones formed ~60 colonies after 5 weeks; antisense clones formed 0–3 colonies. In HeLa S3 cells, wild-type and sense clones formed 218–291 colonies in soft agar after 2 weeks; antisense clones formed 14–160 colonies. There was a good correlation between IGF-IR down-regulation level and inhibition of transformation in soft agar. Tumorigenesis in nude mice was strongly inhibited in HeLa S3 and SiHa clones transfected with the antisense. These results indicate that down-regulation of IGF-IR by antisense RNA can reverse the transformed phenotype of human cervical cancer cells, even when harboring malignant type HPVs.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
In recent years, it has become clear that IGF-IR,3 activated by its ligands, plays different roles in vitro or in vivo (1) : (a) the IGF-IR is mitogenic, although it is required for optimal growth in conjunction with other growth factors, such as epidermal growth factor and platelet-derived growth factor (2 , 3) ; (b) it is quasi-obligatory for the establishment and maintenance of the transformed phenotypes (4, 5, 6) ; and (c) it protects cells from apoptosis induced by a large variety of mechanisms (7, 8, 9, 10, 11) . Interference with the expression and/or activation of the IGF-IR by antisense strategies (12, 13, 14, 15, 16, 17) , dominant-negative mutants (18, 19, 20, 21) , or triple-helix formation (22) reverse the transformed phenotype or inhibit tumorigenicity in many rodent and human cancer cells. Furthermore, antisense strategies (17) , a myristylated COOH terminus of the IGF-IR (23) , and dominant-negative mutants of the IGF-IR (20) cause massive apoptosis in vivo. Because substantial data support that normal cell growth is much less dependent on the IGF-IR (1) , interference with the IGF-IR would be a good candidate for human gene therapy in many types of tumors.

R- cells, originating from mouse embryo with a targeted disruption of IGF-I receptor gene (24 , 25) , are known to be refractory to transformation by several viral and cellular oncogenes. SV40 T antigen, even with activated ras (26 , 27) , bovine papillomavirus E5 protein (28) , activated c-src (29) , and other growth factor receptors that are overexpressed (30 , 31) fail to transform R- cells. However, it was reported that stable transfection of both E6 and E7 oncoproteins of HPV-16 could transform R- cells in soft agar (32) . By using R- cells and their wild-type littermate W cells, it has become clear that the IGF-IR is a necessary requirement for the E7-induced transformation of these fibroblasts (32) . In R- cells, combination of both E6 and E7 transforms R- cells, indicating that E6 may be acting equally to the IGF-IR (32) . In the presence of both E6 and E7 in cervical cancer cells, it is postulated that these two proteins might use an alternative pathway for transformation, and that the interference with the IGF-IR might result in failure to reverse the transformed phenotypes of cervical cancer cells.

In cervical cancer cells, it is well known that in >85% of the patients, the cells are positive for HPV (33 , 34) . In these cervical cancer cells with malignant-type HPVs, E6 protein may play an alternative role for IGF-IR and promote E7-induced transformation, even in the absence of IGF-IR (32) . The present study is undertaken to elucidate whether the IGF-IR targeting can be used for reversal of the transformed phenotypes of cervical cancer cells in vitro by stable transfection of an antisense mRNA expression plasmid into HPV-positive and HPV-negative human cervical cancer-derived cell lines.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Lines.
C33a, SiHa, and HeLa S3 are cell lines originally derived from human cervical carcinomas. All of these cell lines were obtained from the Department of Cell Biology, Institute of Cellular and Molecular Biology, Okayama University Medical School. All of the cell lines were passed in DMEM supplemented with 10% FBS. Status of HPV and major tumor suppressor genes p53 and pRB in these cell lines was characterized previously in detail. SiHa cells contain type 16 HPV, and HeLa S3 cells contain type 18 HPV. C33a cells do not contain any types of HPV (35 , 36) . SiHa and HeLa S3 cells carry wild-type p53 and pRB. Only C33a cells have p53 mutation at codon 273 and pRB in-frame deletion in exon 20 (37) . R+ cells are R- cells stably transfected with human IGF-IR and express about 9.0 x 105 receptors/cell (27 , 38) .

Plasmid Transfections.
The expression vectors HSP-IGF-IRS and HSP-IGF-IRAS (39) produce sense or antisense mRNA to the first 309 bp of cDNA fragment of IGF-IR including a 30-amino acid signal peptide sequence under the control of Drosophila HSP70 promoter (40) . Transfections of plasmids were performed using Transfectam (Promega) under the strict selection of G418. To establish stable transformants with higher copy numbers, selection was performed at a permissive temperature of 34°C in 2.0, 1.5, and 1.0 mg/ml G418 for HeLa S3, SiHa, and C33a cells, respectively. Established clones were kept growing at 37°C until use.

Cell Growth in Monolayer.
Cells were plated at a concentration of 5 x 104 per 35-mm plate in DMEM containing 10% FBS. After 24 h incubation at 37°C, cells were washed three times with Hank’s solution, and medium was replaced with SFM (DMEM supplemented with 0.1% BSA and 50 µg/ml transferrin), or SFM with 20 ng/ml IGF-I (Life Technologies, Inc.), or DMEM with 10% FBS. Cells were incubated for an additional 48 and 96 h, and cell numbers were counted in a hemocytometer. For antisense and sense clones, cells were passed several times at 39°C in advance, and then cells were incubated in each condition for 48 h at 39°C and counted. All of the points were the results of triplicate experiments.

Western Blotting.
Sense and antisense clones maintained at 37°C were shifted to either 34°C or 39°C. After several passages at each temperature, cells were washed three times with Hank’s solution and then incubated for an additional 72 h in SFM. Fresh SFM was renewed every 24 h. Subconfluent cells were lysed in a lysis buffer as described previously. Fifty µg of total cell lysates were separated and hybridized with anti-ß-subunit of IGF-IR (C-20; Santa Cruz Biotechnology).

Colony Formation in Soft Agar.
Sense or antisense clones were passed several times in media without G418 at 39°C prior to seeding in soft agar plates. HeLa S3-derived clones were seeded at 5 x 103 cells/35 mm plate in DMEM supplemented with 10% FBS and 0.2% agarose with 0.5% agarose underlay, and colonies >125 µm in diameter were counted after 2 weeks incubation at 39°C. SiHa- and C33a-derived clones were seeded at 3 x 104 cells/35-mm plate, and the same sized colonies were counted after 4–5 weeks incubation at 39°C.

Tumorigenesis in Nude Mice.
Cells were washed three times with Hank’s solution and incubated in SFM for 24 h, trypsinized, and washed twice with PBS. Cells (5 x 106) were resuspended in 100 µl of sterile PBS and injected s.c. above the hind leg of male BALB/c nude mice (Charles River Breeders).


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
IGF-IR Expression Levels in Cervical Cancer Cell Lines.
To determine expression levels of the IGF-IR in cervical cancer cell lines, whole-cell lysates were collected from each cell line incubated previously at 37°C. Fifty µg of lysates were separated on a 5–15% gradient acrylamide gel and stained with anti-ß-subunit of IGF-IR (Fig. 1)Citation . Lanes 1 and 5 show negative and positive controls from lysates of R- cells and R+ cells. The R+ lane was intentionally overexposed to show the low expression levels of cervical cancer cell lines. We used this Western blot for comparison rather than Scatchard plot analysis since Scatchard plots were often erratic because of the presence of abundant IGF binding proteins secreted from cancer cell lines. C33a shows only a slight signal of the IGF-IR at longer exposure (Fig. 1B)Citation . IGF-IR numbers were roughly calculated from comparison by densitometry with several standard cell lysates, the receptor numbers of which were already determined (38) and summarized in Table 1Citation .



View larger version (26K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Original IGF-IR expression levels in cervical cancer cell lines. Expression levels of cervical cancer cell lines were evaluated by Western blot. Fifty µg of each lysates were blotted with an antibody to the ß-subunit of the IGF-IR. A: Lanes 1, R- cells; Lane 2, C33a cells; Lane 3, HeLa S3 cells; Lane 4, SiHa cells; Lane 5, R+ cells. B: Lane 1, R- cells; Lane 2, C33a cells. Arrow, the ß-subunit of the IGF-IR is detected as Mr 97,000 protein above the nonspecific bands.

 

View this table:
[in this window]
[in a new window]

  		Table 1 IGF-IR expression levels in cervical cancer cell lines

Fifty µg of total lysates from each cell lines were blotted with the anti-ß-subunit of the IGF-IR, and then the IGF-IR number of each cell line was roughly calculated by densitometry by comparison with standard cell lines (described in text).

 
IGF-I Dependency of Cervical Cancer Cell Lines in Monolayer Growth.
Each cervical cancer cell line was incubated under various IGF-I concentrations in monolayer, and their IGF-I ligand dependency was evaluated (Fig. 2)Citation . Sole addition of IGF-I stimulated growth of all cell lines tested in the study, and it depended on IGF-IR expression levels, shown in Table 1Citation . We repeated this experiment for the C33a cell line, which has the lowest IGF-IR number, and confirmed that IGF-I stimulation had a slight but definitely reproducible mitogenic effect.



View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. IGF-I ligand dependency of cervical cancer cell lines in monolayer growth. Cells (5 x 104) of HeLa S3 (A), SiHa (B), and C33a wild-type (C) were seeded in six-well plates in 10% FBS and incubated for 24 h. Then the medium was replaced with either SFM ({blacktriangleup}), 0.2 ng/ml ({circ}), 2 ng/ml (•), or 20 ng/ml ({square}) of IGF-I or 10% FBS ({blacksquare}). Cell number was counted after 48 and 96 h incubation in each medium.

 
Down-Regulation of IGF-IR Expression Levels by Antisense RNA.
Established stable clones with sense or antisense were shifted to 34°C or 39°C and passed several times. Because the transfected IGF-IR antisense is controlled under the thermosensitive HSP70 promoter (40) , transcription of the antisense mRNA is on when clones are kept at 39°C, and it is off at 34°C. After serum deprivation for 72 h, lysates were collected from subconfluent cells, and the difference between the two temperatures was compared on Western blot. Fig. 3Citation shows the down-regulation of the IGF-IR expression in HeLa S3 antisense clones. There is a large variety of down-regulation levels among antisense clones. Because HeLa S3 cells express 7–44 times more IGF-IR than the other two cervical cancer cell lines, integration of multiple copy number seems necessary to get enough down-regulation for this cell line. In SiHa clones with antisense transfected, IGF-IR signals at 39°C could not be detected. C33a cells express only a little amount of receptor, and IGF-IR signal of either C33a antisense or C33a sense clones could not be clearly detected after 60 min exposure (data not shown).



View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Down-regulation of IGF-IR expression levels in HeLa S3 clones transfected with a plasmid expressing an antisense RNA to the IGF-IR. Down-regulation of the IGF-IR by antisense is shown in the Western blot, where cell lysates collected either at 34°C or 39°C were stained with an antibody to the ß-subunit of the IGF-IR. wt, wild type.

 
Down-Regulation of IGF-IR Slightly Inhibited Mitogenicity in Monolayer.
Sense and antisense clones, as well as wild-type cells of the three cervical cancer cell lines, were examined for their mitogenicity in monolayer. Cells were incubated at 39°C without G418 and used for the study. Cell growth in SFM, SFM supplemented with 20 ng/ml IGF-I, and DMEM with 10% FBS was assessed as percentage of increase after 48 h of incubation (Fig. 4)Citation . Although there are some clonal variations, antisense clones of these three cell lines showed slightly inhibited monolayer growth than wild-type and sense transfected clones. Antisense clones showed ~20% inhibition on the average but was not statistically significant.



View larger version (31K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Monolayer growth of cervical cancer cell-derived clones. Monolayer growth of HeLa S3 (A), SiHa (B), and C33a (C) derived clones are shown. Cells were plated at a density of 5 x 104 cells in six-well plates and incubated for 24 h in 10% serum. The growth medium was replaced (time 0) either with SFM ({square}), SFM supplemented with 20 ng/ml IGF-I (), or 10% FBS ({blacksquare}). The number of cells was determined after an additional 48 h of incubation in each medium and is expressed as percentage of increase over number of cells at time 0. S, sense transfected clones; AS, antisense transfected clones. Bars, SD.

 
IGF-IR Antisense RNA Suppressed Colony Formation in Soft Agar.
Sense, antisense, and wild-type cells of these three cervical cancer cell lines were passed several times at 39°C, seeded into 0.2% soft agar plates, and incubated at 39°C. HeLa S3 cells were originally highly transforming, and 5 x 103 wild-type cells seeded in a 35-mm plate formed many colonies after 2 weeks of incubation. SiHa and C33a cells were much less transforming, so that cells at higher density (3 x 104 per 35-mm plate) and longer incubation time (4 weeks for C33a and 5 weeks for SiHa) were necessary to obtain enough colonies, again confirming the much higher expression level of the IGF-IR in HeLa S3 cells. Colony number in soft agar is summarized in Table 2Citation . In SiHa- and C33a-derived clones, the original IGF-IR expression levels of which were low, there is significant difference in colony formation in soft agar between antisense transfected clones and sense clones or wild-type cells. In HeLa S3 cells expressing much higher IGF-IR, colony numbers of antisense clones vary from 14 to 160. Suppression of transforming ability in soft agar and levels of the IGF-IR down-regulation estimated by Western blot are compared in Fig. 5Citation . There is a good correlation between colony numbers in soft agar and IGF-IR expression levels, indicating that the integration of large copy numbers of antisense RNA-expressing plasmid is necessary to achieve enough down-regulation of the IGF-IR and to reverse transforming phenotype of these aggressive HeLa S3 cells.


View this table:
[in this window]
[in a new window]

  		Table 2 Transformation in soft agar of cervical cancer-derived clones

Cells (5 x 103) for HeLa S3-derived clones and 3 x 104 cells for SiHa- and C33a-derived clones were plated in 0.2% soft agar plates. Colonies >125 µm in diameter were counted after 2, 5, and 4 weeks incubation for HeLa S3, SiHa, and C33a clones, respectively.

 


View larger version (44K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Correlation between inhibition of transformation and down-regulation of the IGF-IR in HeLa S3 antisense clones. wt, wild type; AS, antisense.

 
Tumorigenesis in Nude Mice.
The inhibitory effect of the IGF-IR antisense was then tested by injections of transfected clones into nude mice. Because C33a wild-type cells are not tumorigenic in nude mice, only HeLa S3- and SiHa-derived clones were tested. HeLa S3 wild-type and sense clones formed palpable tumors 2–3 days after injection, and balky tumors progressed rapidly. In contrast, representative antisense clones did not form any tumors until 1 week, and very small palpable tumors (<2 mm in diameter) remained unchanged for 4 weeks (Fig. 6)Citation . SiHa wild-type and sense clones formed palpable tumors after 1 week to 10 days and grew slowly; SiHa antisense clones did not form any tumors after 4 weeks.



View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 6. Tumorigenicity of HeLa S3-derived clones in nude mice. Three representative antisense transfected clones as well as sense clones and wild-type cells were injected s.c. into nude mice, and their tumorigenicity in vivo was monitored until 4 weeks after injection. AS, antisense.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Genomic integration of high-risk types of HPV has been strongly associated in cervical and other anogenital malignancies (33) . It is well known that the oncogenic properties of malignant HPVs depend on the E6 and E7 proteins, which are capable of inactivating two major suppressor genes, p53 and pRB. E6 binds to p53 and promotes its ubiquitin-dependent proteolysis (41) . E7 binds preferentially to hypophosphorylated pRB and inhibits binding of pRB to transcriptional factor E2F (42) . Although E6 and/or E7 are known to transform NIH 3T3 cells and immortalize human primary cultured keratinocytes (43) , E6 and E7 are not enough for carcinogenesis. Within the high-risk HPV-positive lesions, where both tumor suppressor proteins pRB and p53 are functionally inactivated by the expression of E6 and E7 proteins, only a small number of the lesions will progress to carcinomas. As another causative alteration, frequent loss of heterozygosity in chromosomal arms likely to harbor other tumor suppressor genes is reported from human cervical intraepithelial neoplasia patient specimens (44) .

IGF-I and IGF-IR also play an important role in cell transformation induced by viral oncogenes (45) . SV40 T antigen induces constitutive tyrosyl autophosphorylation of the IGF-IR (46) . SV40 T antigen up-regulates IGF-I ligand expression and binds directly to IRS-1, the major downstream substrate of the IGF-IR (47) . v-src also induces marked tyrosyl autophosphorylation of the IGF-IR (48) . BPV E5 directly binds and activates platelet-derived growth factor ß receptor (49) and might transactivate IGF-IR through the platelet-derived growth factor ß receptor (31) . The fact that R- cells are refractory to transformation by these viral oncogenes is striking (26 , 28) . The only viral oncogene that is reported to transform R- cells by itself is the coexpression E6 and E7 of HPV-16 and v-src thus far (29 , 32) . Interestingly, SV40 T antigen, which does not transform R- cells, is known to suppress both pRB and p53, similar to E6 and E7 of HPV. E6 binds to p53 and induces its degradation, whereas SV40 T antigen just binds stably to p53 and inactivates its function. The difference between HPV E6/E7 and SV40 T antigen in transforming ability in the absence of the IGF-IR still remains unknown. E6 was reported to have a protective effect from staurosporine-induced apoptosis, even in p53-/- cells, indicating the probability of a p53-independent pathway of E6 for cell survival signaling (32) . In contrast, the IGF-IR is also reported to have strong protective effects against apoptosis induced by a large variety of causes (7, 8, 9, 10, 11) . Steler et al. (32) hypothesized that the IGF-IR and E6 were functionally equivalent in transformation. It is likely that overexpressing E6 and E7 substitute the transforming ability of the IGF-IR, but a mechanism(s) of E6 and E7 for transforming R- cells involves not only the abrogation of two major suppressor gene functions but also substitution of some other properties of the IGF-IR. If E6 cooperates with E7 to send transforming and antiapoptotic signaling that is independent of the IGF-IR pathways, interference with the IGF-IR cannot be effective for transformed cells harboring malignant type HPVs, such as cervical cancer cells.

The present study shows that the down-regulation of the IGF-IR by antisense strategy is effective in the reversal of transformed phenotypes in vitro and in vivo for human cervical cancer cell lines in the presence (HPV-16 in SiHa and HPV-18 in HeLa S3) and absence (C33a) of HPV. Antisense oligonucleotide for HPV-16 E6 and E7 (50) , antisense RNA against HPV-16 E6/E7 (51) , and single-chain antibody against HPV-16 E7 (52) were tried previously in SiHa cells, and they all inhibited transformation. But all of them were tried in SiHa cells, which contain only one to two copies of integrated HPV-16 DNA and express relatively low amounts of IGF-IR (Table 1)Citation . In contrast, HeLa S3 cells contain ~50 copies of integrated HPV-18 and express huge numbers of the IGF-IR (Table 1)Citation . HeLa S3 cells are highly transforming and make many more colonies in soft agar than SiHa cells. In SiHa and C33a cells, with lower IGF-IR expression and lower or no HPV integration, stable expression of the antisense mRNA against the IGF-IR resulted in marked suppression of colony formation in soft agar. In HeLa S3 clones with an antisense effect against the IGF-IR, some clones still formed colonies when the antisense effect was not overwhelming. But results from antisense clones with sufficient down-regulation of the IGF-IR were promising, and suppression of colony formation in soft agar was closely correlated with the down-regulation of the IGF-IR. Furthermore, it is clear that this biological effect on antisense clones is not attributable to the toxicity of overexpressing mRNAs, because no toxicity is observed in sense clones, and its action depends mainly on the condition of anchor independence. Although there is variation in the IGF-IR expression levels and integrated HPV copy numbers among human cervical cancer cells, our data from HeLa S3 clones clearly show that down-regulation of the IGF-IR, if sufficient, can reverse transformed phenotypes of cervical cancer cells, even with malignant-type HPVs.

Targeting the IGF-IR for cervical cancer cells seems ideal, now that it is confirmed that it can reverse transformed phenotypes, even in the presence of high copy number of malignant-type HPV, because: (a) it can be widely applied for all types of cervical cancer cells, regardless of specific HPV subtypes; (b) it can be also used in the absence of HPV; (c) normal cells are less dependent on the IGF-IR for growth; and (d) antimitogenic, antitransforming, and proapoptotic effects arising from interference with the IGF-IR pathways are usually more dramatically emphasized in vivo than in vitro.


   ACKNOWLEDGMENTS
 
We thank Dr. R. Baserga, Kimmel Cancer Center, for kindly providing HSP-IGF-IRS and AS (or HSP-EGF-ERAS) expression vectors, R- and R+ cells.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported in part by Grant-in-Aid for Scientific Research 10671544 (to A. H.) and Grant 09671684 (to M. Y.) from the Ministry of Education, Science, Sports and Culture of Japan. Back

2 To whom requests for reprints should be addressed, at Department of Obstetrics and Gynecology, Okayama University Medical School, 2-5-1 Shikata, Okayama 700-8558, Japan. Phone: 81-86-235-7890; Fax: 81-86-225-9570. Back

3 The abbreviations used are: IGF-IR, insulin-like growth factor I receptor; FBS, fetal bovine serum; HSP, heat shock protein; SFM, serum-free medium; HPV, human papillomavirus. Back

Received 8/16/99. Accepted 12/ 2/99.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Baserga R., Hongo A., Rubini M., Prisco M., Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim. Biophys. Acta, 1332: 105-126, 1997.
  2. Leof E. B., Wharton W., Van Wyk J. J., Pledgar W. J. Epidermal growth factor (EGF) and somatomedin C-regulated G1 progression in competent BALB/c3T3 cells. Exp. Cell Res., 141: 107-115, 1982.[Medline]
  3. Stiles C. D., Capone G. T., Scher C. D., Antodiades H. N., Van Wyk J. J., Pledger W. J. Dual control of cell growth by somatomedins and platelet-derived growth factor. Proc. Natl. Acad. Sci. USA, 76: 1279-1283, 1979.[Abstract/Free Full Text]
  4. Baserga R., Sell C., Porcu P., Rubini M. The role of the IGF-I receptor in the growth and transformation of mammalian cells. Cell Prolif., 27: 63-71, 1994.[Medline]
  5. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth?. Cancer Res., 55: 249-252, 1995.[Abstract/Free Full Text]
  6. Kaleko M., Rutter W. G., Mille A. D. Overexpression of the human insulin-like growth factor I receptor promotes ligand-independent neoplastic transformation. Mol. Cell. Biol., 10: 464-473, 1990.[Abstract/Free Full Text]
  7. Harrington E. A., Bennett M. R., Fanidi A., Evan G. I. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J., 13: 3286-3295, 1994.[Medline]
  8. Sell C., Baserga R., Rubin R. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res., 55: 303-306, 1995.[Abstract/Free Full Text]
  9. Prisco M., Hongo A., Rizzo M. G., Sacchi A., Baserga R. The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal. Mol. Cell. Biol., 17: 1084-1092, 1997.[Abstract]
  10. Nakamura S., Watanabe H., Miura M., Sasaki T. Effect of the insulin-like growth factor I receptor on ionizing radiation-induced cell death in mouse embryo fibroblasts. Exp. Cell. Res., 235: 287-294, 1997.[Medline]
  11. Resnicoff M., Abraham D., Yutanawiboonchai W., Rotman H., Kajstura J., Rubin R., Zoltick P., Baserga R. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res., 55: 2463-2469, 1995.[Abstract/Free Full Text]
  12. Trojan J., Johnson T. R., Rudin S. D., Ilan M., Tykocinski M., Ilan J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science (Washington DC), 259: 94-97, 1993.[Abstract/Free Full Text]
  13. Resnicoff M., Sell C., Rubini M., Coppola D., Ambrose D., Baserga R., Rubin R. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-I (IGF-I) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res., 54: 2218-2222, 1994.[Abstract/Free Full Text]
  14. Resnicoff M., Coppola D., Sell C., Rubin R., Ferrone S., Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res., 54: 4848-4850, 1994.[Abstract/Free Full Text]
  15. Shapiro D. N., Jones B. G., Shapiro L. H., Dias P., Houghton P. J. Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J. Clin. Investig., 94: 1235-1242, 1994.
  16. Neuenschwander S., Roberts C. T., Jr., LeRoith D. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology, 136: 4298-4303, 1995.[Abstract]
  17. Burfeind P., Chernicky C. L., Rininsland F., Ilan J., Ilan J. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc. Natl. Acad. Sci. USA, 93: 7263-7268, 1996.[Abstract/Free Full Text]
  18. Prager D., Li H. L., Asa S., Melmed S. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc. Natl. Acad. Sci. USA, 91: 2181-2185, 1994.[Abstract/Free Full Text]
  19. Burgaud J. L., Resnicoff M., Baserga R. Mutant IGF-I receptors as dominant negatives for growth and transformation. Biochem. Biophys. Res. Commun., 214: 475-481, 1995.[Medline]
  20. D’Ambrosio C., Ferber A., Resnicoff M., Baserga R. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res., 56: 4013-4020, 1996.[Abstract/Free Full Text]
  21. Reiss K., D’Ambrosio C., Tu X., Tu C., Baserga R. Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. Clin. Cancer Res., 4: 2647-2655, 1998.[Abstract]
  22. Rininsland F., Johnson T. R., Chernicky C. L., Schulze E., Burfeind B., Ilan J. Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells. Proc. Natl. Acad. Sci. USA, 94: 5854-5859, 1997.[Abstract/Free Full Text]
  23. Hongo A., Yumet G., Resnicoff M., Romano G., O’Connor R., Baserga R. Inhibition of tumorigenesis and induction of apoptosis in human tumor cells by the stable expression of a myristylated COOH terminus of the insulin-like growth factor I receptor. Cancer Res., 58: 2477-2484, 1998.[Abstract/Free Full Text]
  24. Liu J. P., Baker J., Perkins A. S., Robertson E. J., Efstratiadis A. Mice carrying null mutation of the gene encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell, 75: 59-72, 1993.[Medline]
  25. Baker J., Liu J. P., Robertson E. J., Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell, 75: 73-82, 1993.[Medline]
  26. Sell C., Rubini M., Liu J. P., Efstratiadis A., Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc. Natl. Acad. Sci. USA, 90: 11217-11221, 1993.[Abstract/Free Full Text]
  27. Sell C., Dumenil G., Deveaud C., Miura M., Coppola D., DeAngelis T., Rubin R., Efstratiadis A., Baserga R. Effect of a null mutation of the type 1 IGF receptor gene on growth and transformation of mouse embryo fibroblasts. Mol. Cell. Biol., 14: 3604-3612, 1994.[Abstract/Free Full Text]
  28. Morrione A., DeAngelis T., Baserga R. Failure of the bovine papillomavirus to transform mouse embryo fibroblasts with a targeted disruption of the insulin-like growth factor I receptor genes. J. Virol., 69: 5300-5303, 1995.[Abstract]
  29. Valentinis B., Morrione A., Taylor S. J., Baserga R. Insulin-like growth factor I receptor signaling in transformation by src oncogene. Mol. Cell Biol., 17: 3744-3754, 1997.[Abstract]
  30. Coppola D., Ferber A., Miura M., Sell C., D’Ambrosio C., Rubin R., Baserga R. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol. Cell. Biol., 14: 4588-4595, 1994.[Abstract/Free Full Text]
  31. DeAngelis T., Ferber A., Baserga R. Insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the platelet-derived growth factor receptor. J. Cell. Physiol., 164: 214-221, 1995.[Medline]
  32. Steler M. A., Zou Z., Schiller J. T., Baserga R. Transformation by human papillomavirus 16 E6 and E7: role of the insulin-like growth factor 1 receptor. Cancer Res., 56: 5087-5091, 1996.[Abstract/Free Full Text]
  33. zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology, 184: 9-13, 1991.[Medline]
  34. Riou G., Favre M., Jeannel D., Bourhis J., LeDoussal V., Orth G. Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA. Lancet, 335: 1171-1174, 1990.[Medline]
  35. Schwarz E., Freese U. K., Gissmann L., Mayer W., Roggenbuck B., Stremlau A., zur Hausen H. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature (Lond.), 314: 111-114, 1985.[Medline]
  36. Yee C. L., Krishnan-Hewlett I., Baker C. C., Schlegel R., Howley P. M. Presence and expression of human papillomavirus sequence in human cervical carcinoma cell lines. Am. J. Pathol., 119: 3261-3266, 1985.
  37. Scheffner M., Münger K., Byrne J. C., Howley P. M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA, 88: 5523-5527, 1991.[Abstract/Free Full Text]
  38. Rubini M., Hongo A., D’Ambrosio C., Baserga R. The IGF-I receptor in mitogenesis and transformation of mouse embryo cells: role of receptor number. Exp. Cell Res., 230: 284-292, 1997.[Medline]
  39. Ambrose D., Resnicoff M., Coppola D., Sell C., Miura M., Jameson S., Baserga R., Rubin R. Growth regulation of human glioblastoma T98G cells by insulin-like growth factor-1 and its receptor. J. Cell. Physiol., 159: 92-100, 1994.[Medline]
  40. Craig E., McCathy B. J., Wadsworth S. C. Sequence organization of two recombinant plasmids containing genes for the major heat shock-induced protein of D. melanogaster. Cell, 16: 575-588, 1979.[Medline]
  41. Scheffner M., Werness B. A., Huibregtse J. M., Levine A. J., Howley P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63: 1129-1136, 1990.[Medline]
  42. Dyson M., Howley P. M., Münger K., Harlow E. The human papillomavirus 16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science (Washington DC), 243: 934-937, 1989.[Abstract/Free Full Text]
  43. Münger K., Phelps W. C., Bubb V., Howley P. M., Schelegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol., 63: 4417-4421, 1989.[Abstract/Free Full Text]
  44. Larson A. A., Liao S. Y., Stanbridge E. J., Cavenee W. K., Hampton G. M. Genetic alterations accumulate during cervical tumorigenesis and indicate a common origin for multifocal lesions. Cancer Res., 57: 4171-4176, 1997.[Abstract/Free Full Text]
  45. Drummond-Barbosa D., DiMaio D. Virocrine transformation. Biochim. Biophys. Acta, 1332: M1-M17, 1997.[Medline]
  46. Porcu P., Ferber A., Pietrzkowski Z., Roberts C. T., Adamo M., LeRoith D., Baserga R. The growth-stimulatory effect of simian virus 40 T antigen requires the interaction of insulin-like growth factor 1 with its receptor. Mol. Cell. Biol., 12: 5069-5077, 1992.[Abstract/Free Full Text]
  47. Zhou-li F., D’Ambrosio C., Li S., Surmacz E., Baserga R. Association of insulin receptor substrate 1 with simian virus 40 large T antigen. Mol. Cell. Biol., 15: 4232-4239, 1995.[Abstract]
  48. Kozma L. M., Weber M. J. Constitutive phosphorylation of the receptor for insulin-like growth factor I in cells transformed by the src oncogene. Mol. Cell. Biol., 10: 3626-3634, 1990.[Abstract/Free Full Text]
  49. Petti L., DiMaio D. Stable association between the bovine papillomavirus E5 transforming protein and activated platelet-derived growth factor receptor in transformed mouse cells. Proc. Natl. Acad. Sci. USA, 89: 6736-6740, 1992.[Abstract/Free Full Text]
  50. Tan T. M., Ting R. C. In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Res., 75: 4599-4605, 1995.
  51. Hamada K., Sakaue M., Alemany R., Zhang W. W., Horio Y., Roth J. A., Mitchell M. F. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. Gynecol. Oncol., 63: 219-227, 1996.[Medline]
  52. Wang-Johanning F., Gillespie G. Y., Grim J., Rancourt C., Alvarez R. D., Siegal G. P., Curiel D. T. Intracellular expression of a single-chain antibody directed against human papillomavirus type 16 E7 oncoprotein achieves targeted antineoplastic effects. Cancer Res., 58: 1893-1900, 1998.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
T. G. Harris, R. D. Burk, H. Yu, H. Minkoff, L. S. Massad, D. H. Watts, Y. Zhong, S. Gange, R. C. Kaplan, K. Anastos, et al.
Insulin-Like Growth Factor Axis and Oncogenic Human Papillomavirus Natural History
Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 245 - 248.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. Li, Z. He, S. Ermakova, D. Zheng, F. Tang, Y.-Y. Cho, F. Zhu, W.-Y. Ma, Y. Sham, E. A. Rogozin, et al.
Direct Inhibition of Insulin-Like Growth Factor-I Receptor Kinase Activity by (-)-Epigallocatechin-3-Gallate Regulates Cell Transformation
Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 598 - 605.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt
The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights
Endocr. Rev., February 1, 2007; 28(1): 20 - 47.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M.-R. Shen, Y.-M. Hsu, K.-F. Hsu, Y.-F. Chen, M.-J. Tang, and C.-Y. Chou
Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by {alpha}v{beta}3 integrin signaling
Carcinogenesis, May 1, 2006; 27(5): 962 - 971.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. L. Gable, B. A. Maddux, C. Penaranda, M. Zavodovskaya, M. J. Campbell, M. Lobo, L. Robinson, S. Schow, J. A. Kerner, I. D. Goldfine, et al.
Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth.
Mol. Cancer Ther., April 1, 2006; 5(4): 1079 - 1086.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
A. Yamamoto, M. L. Cremona, and J. E. Rothman
Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway
J. Cell Biol., February 27, 2006; 172(5): 719 - 731.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Kaneda and A. P. Feinberg
Loss of Imprinting of IGF2: A Common Epigenetic Modifier of Intestinal Tumor Risk
Cancer Res., December 15, 2005; 65(24): 11236 - 11240.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Hongo, H. Kuramoto, Y. Nakamura, K. Hasegawa, K. Nakamura, J. Kodama, and Y. Hiramatsu
Antitumor Effects of a Soluble Insulin-Like Growth Factor I Receptor in Human Ovarian Cancer Cells: Advantage of Recombinant Protein Administration in Vivo
Cancer Res., November 15, 2003; 63(22): 7834 - 7839.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Blum, A. Gazit, and A. Levitzki
Development of New Insulin-like Growth Factor-1 Receptor Kinase Inhibitors Using Catechol Mimics
J. Biol. Chem., October 17, 2003; 278(42): 40442 - 40454.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Baars, A. Bachmann, A. Levitzki, and F. Rosl
Tyrphostin AG 555 Inhibits Bovine Papillomavirus Transcription by Changing the Ratio between E2 Transactivator/Repressor Function
J. Biol. Chem., September 26, 2003; 278(39): 37306 - 37313.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Wu, G. Tortolero-Luna, H. Zhao, D. Phatak, M. R. Spitz, and M. Follen
Serum Levels of Insulin-like Growth Factor I and Risk of Squamous Intraepithelial Lesions of the Cervix
Clin. Cancer Res., August 1, 2003; 9(9): 3356 - 3361.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
D. E. Hansel, A. Rahman, M. Hidalgo, P. J. Thuluvath, K. D. Lillemoe, R. Shulick, J.-L. Ku, J.-G. Park, K. Miyazaki, R. Ashfaq, et al.
Identification of Novel Cellular Targets in Biliary Tract Cancers Using Global Gene Expression Technology
Am. J. Pathol., July 1, 2003; 163(1): 217 - 229.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
J. I. Leu, M. A. S. Crissey, L. E. Craig, and R. Taub
Impaired Hepatocyte DNA Synthetic Response Posthepatectomy in Insulin-Like Growth Factor Binding Protein 1-Deficient Mice with Defects in C/EBP{beta} and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Regulation
Mol. Cell. Biol., February 15, 2003; 23(4): 1251 - 1259.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Reinmuth, W. Liu, F. Fan, Y. D. Jung, S. A. Ahmad, O. Stoeltzing, C. D. Bucana, R. Radinsky, and L. M. Ellis
Blockade of Insulin-like Growth Factor I Receptor Function Inhibits Growth and Angiogenesis of Colon Cancer
Clin. Cancer Res., October 1, 2002; 8(10): 3259 - 3269.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Tezuka, H. Watanabe, S. Nakamura, D. Yu, W. Aung, T. Sasaki, H. Shibuya, and M. Miura
Antiapoptotic Activity Is Dispensable for Insulin-like Growth Factor I Receptor-mediated Clonogenic Radioresistance after {gamma}-Irradiation
Clin. Cancer Res., October 1, 2001; 7(10): 3206 - 3214.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Reiss, X. Tu, G. Romano, F. Peruzzi, J. Y. Wang, and R. Baserga
Intracellular Association of a Mutant Insulin-like Growth Factor Receptor with Endogenous Receptors
Clin. Cancer Res., July 1, 2001; 7(7): 2134 - 2144.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
A. Muratovska, R. N. Lightowlers, R. W. Taylor, D. M. Turnbull, R. A. J. Smith, J. A. Wilce, S. W. Martin, and M. P. Murphy
Targeting peptide nucleic acid (PNA) oligomers to mitochondria within cells by conjugation to lipophilic cations: implications for mitochondrial DNA replication, expression and disease
Nucleic Acids Res., May 1, 2001; 29(9): 1852 - 1863.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakamura, K.
Right arrow Articles by Kudo, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakamura, K.
Right arrow Articles by Kudo, T.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online